Hormone replacement therapy (HRT): further information on the known increased risk of breast cancer with HRT and its persistence after stopping

New data have confirmed that the risk of breast cancer is increased during use of all types of HRT, except vaginal estrogens, and have also shown that an excess risk of breast cancer persists for longer after stopping HRT than previously thought.

Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus

Establish hepatitis B virus status before initiating daratumumab and in patients with unknown hepatitis B virus serology who are already being treated with daratumumab.

Naltrexone/bupropion (Mysimba▼): risk of adverse reactions that could affect ability to drive

Advise patients that naltrexone/bupropion has been associated with adverse reactions such as dizziness or somnolence, which can affect ability to drive, operate machinery, or perform dangerous tasks.

Carfilzomib (Kyprolis▼): reminder of risk of potentially fatal cardiac events

Anti-cancer therapy with carfilzomib has been associated with cases of cardiac arrest, cardiac failure, and myocardial infarction, including in patients without pre-existing cardiac disorders.

Letters and drug alerts sent to healthcare professionals in July 2019

Letters were sent about Oncaspar▼ (pegaspargase), Ketalar (ketamine) injection, and Elmiron (pentosan polysulfate sodium).

Medical Devices Alerts issued in July 2019

Alerts were issued about Telefunken automated external defibrillators and BD Microtainer capillary blood specimen collection tubes.

Posted on the UK MHRA website on 19 August 2019